Kemwell expands work in Sweden at former Pfizer plant


Contract manufacturer Kemwell will produce drugs for Mercury Pharma at a plant that it bought in 2006 from Pfizer ($PFE). While it still has capacity at the facility, the company said it has nailed down three other contracts, proof that drugmaking in Sweden is on the rise, reports. "This contract with Mercury is very valuable for us and a most interesting contract in manufacturing but also a proof that Sweden is a competitive country in pharmaceutical production," business development manager Leo Fallgren told the publication. The India-based company added to the 16,000-square-meter former Pfizer plant in 2010, boosting its operations space to 31,000 square meters. Mercury Pharma, a U.K.-based specialty drugmaker, was recently acquired by Cinven for £465 million ($756 million). Story | More

Filed Under